Our results indicated that PROTAC EZH2 degrader-1 could overcome resistance by inhibiting EZH2 and suppressing tumour growth, which contradicts previous reports showing that EZH2 is responsible for drug resistance in SCLC [20, 21, 40]. This evidence concerns the gene EZH2 and neoplasm.